Related Experiment Video
Updated: Oct 20, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Randomized clinical trials eliminate treatment assignment bias. However, mediators of treatment effects, like biomarkers, require careful consideration in trial design and analysis for patient-specific insights.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Translational Oncology
Background:
- Randomized clinical trials (RCTs) utilize random allocation to eliminate confounding biases in treatment assignment.
- Confounders affecting treatment effect mediators remain unaddressed by randomization and necessitate specific analytical strategies.
- Biomarkers predictive of targeted therapy response in oncology exemplify such mediators, influencing treatment efficacy.
Purpose of the Study:
- To highlight the limitations of randomization concerning treatment effect mediators.
- To emphasize the importance of considering these mediators in clinical trial design and statistical modeling.
- To explore the integration of experimental and observational data for enhanced patient-specific inferences.
Main Methods:
- Review of randomization principles in clinical trials.
- Identification of mediators influenced by confounders.
- Conceptual framework for fusing experimental (RCT) and observational data.
Main Results:
- Randomization effectively controls for treatment assignment bias.
- Confounders influencing treatment mediators are not controlled by randomization.
- Observational data provide prognostic insights into outcome heterogeneity.
- Integrating RCT and observational data enables patient-specific treatment inferences.
Conclusions:
- Clinical trial design must account for confounders impacting treatment mediators.
- Biomarker-guided patient selection is crucial for targeted therapies.
- Combining experimental and observational data offers a powerful approach for personalized medicine and understanding treatment effects.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Related Concept Videos
Blinding
Confounding in Epidemiological Studies
Randomized Experiments
Simple randomization
Simple...
Bias in Epidemiological Studies
Bias
In statistics, a sampling bias is created when a sample is collected from a population, and some members of the population are not as likely to be chosen as others (remember, each member...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...